Fisher & Paykel Healthcare Corporation Limited today reported record net profit after tax of NZ$113.2 million for the full year, an increase of 17% over the prior year.
Read more
Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today at its annual shareholders’ meeting that it has raised its earnings guidance for the financial year ending 31...
Fisher & Paykel Healthcare Corporation Limited today announced its results for the first half of the 2024 financial year.
Fisher & Paykel Healthcare Corporation Limited today announced a record third quarter, with profit from continuing operations of NZ$26.2 million for the three months ended 31 December 2002. Revenue for the three months grew 17% in US dollar terms, compared with the prior compa...
Fisher & Paykel Healthcare Corporation Limited (NZX:FPH, ASX:FPH) announced today that it intends to release on Friday, 27 May 2016 its financial results for the year ended 31 March 2016.
Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) announced today that it intends to release on Thursday, 20 November 2014 its financial results for the six months ended 30 September 2014
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
The heating and humidifying of respiratory gases is crucial for intubated patients. Learn about humidification devices, including active and passive.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
The AIRVO 2 family enables the transition of Optiflow therapy across critical, non-critical areas of the hospital and into the home.
Humidification for patients using a mask at home
Humidification for patients with a tracheostomy at home
Our newest Airvo features an integrated battery, high-pressure oxygen input and a broader flow range.
Optiflow nasal high flow therapy explained, what is it and how does it work?
F&P Solo™ Nasal is the world’s first AutoFit™ mask. It simplifies setup like no other, using AutoLock™ technology - stretch to fit, touch to adjust.
Airvo, F&P 950 and F&P 850 – this trio of humidification and respiratory support devices facilitate multiple respiratory therapies across the hospital
Join our global team. View and apply for jobs with us.
Get in touch with our team, find a distributor or send an enquire.
We value your privacy. Our websites and applications use cookies to function properly and securely.